Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children

Pediatric Infectious Disease Journal

Volumn 18, Issue 5, 1999, Pages 456-461

  Anabwani, Gabriel ^a   Canfield, Craig J ^b   Hutchinson, David B A ^c,d  

^a MOI UNIVERSITY   (Kenya)

^b Pharmaceutical Systems Inc   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Atovaquone; Halofantrine; Malaria; Malarone; Plasmodium falciparum; Proguanil

Indexed keywords

ATOVAQUONE; HALOFANTRINE; PROGUANIL;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; EPISTAXIS; FEMALE; HUMAN; KENYA; MAJOR CLINICAL STUDY; MALARIA; MALE; MONITORING; MORTALITY; MUSCLE WEAKNESS; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ACUTE DISEASE; ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHILD; CHILD, PRESCHOOL; CHLOROGUANIDE; DRUG THERAPY, COMBINATION; FECES; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; NAPHTHOQUINONES; PHENANTHRENES; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME;

EID: 0032991003     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199905000-00011     Document Type: Article

References (34)

1. World Health Organization. Implementation of the global malaria control strategy. WHO Tech Rep Ser 1993;839:1-25.
2. World Health Organization. World malaria situation in 1992. Weekly Epidemiol Rec 1994;69:309-16.
3. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995;332:1399-404.
4. White NJ. The treatment of malaria. N Engl J Med 1996;335: 800-6.
5. Menge I, Esamai F, van Reken D, et al. Paediatric morbidity and mortality at the Eldoret District Hospital, Kenya. East Afr Med J 1995;72:165-9.
6. Petit PL, van Ginneken JK. Analysis of hospital records in four African countries, 1975-1990, with emphasis on infectious diseases. J Trop Med Hyg 1995;98:217-27.
7. Zucker JR, Barber AM, Paxton LA, et al. Malaria surveillance: United States, 1992. MMWR 1995;44:1-17.
8. Olliaro P, Cattani J, Wirth D. Malaria, the submerged disease. JAMA 1996;275:230-3.
9. Panisko DM, Keystone JS. Treatment of malaria: 1990. Drugs 1990;39:160-89.
10. Bloland PB, Lackritz EM, Kazembe PN, et al. Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis 1993;167:932-7.
11. Zucker JR, Lackritz EM, Ruebush TK, et al. Childhood mortality during and after hospitalization in Western Kenya: effect of malaria treatment regimens. Am J Trop Med Hyg 1996;55:655-60.
12. Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-{trans-4-(4′-chlorphenyl)cyclo-hexyl}-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 1992;43:1545-53.
13. Olliaro PL, Trigg PI. Status of antimalarial drugs under development. Bull WHO 1995;73:565-71.
14. Hudson AT, Dickins M, Ginger CD, et al. 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 1991;17:427-35.
15. Looareesuwan S, Viravan C, Webster HK, et al. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996;54:62-6.
16. Chiodini PL, Conlon CP, Hutchinson DBA, et al. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 1995;36:1073-8.
17. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995;80:373-81.
18. Eriksson B, Bjorkman A, Keisu M. How safe is proguanil? A post-marketing investigation of side effects. Scand J Infect Dis 1991;23:489-93.
19. Hussein Z, Eaves J, Hutchinson DB, et al. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin Pharmacol Ther 1997;61:518-30.
20. Haile LG, Flaherty JF. Atovaquone: a review. Ann Pharmacol 1993;27:1488-93.
21. Looareesuwan S, Wilairatana P, Chalermarut K, et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999;60:526-32.
22. Radloff PD, Philipps J, Nkeyi M, et al. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996; 347:1511-14.
23. de Alencar FEC, Cerutti C Jr., Durlacher RR, et al. Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 1997;175:1544-7.
24. Sabchareon A, Attanath P, Phanuaksook P, et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 1998;92:201-6.
25. Lell B, Luckner D, Ndjave M, et al. Randomized placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998;351:709-13.
26. Watkins WM, Oloo JA, Lury JD, et al. Efficacy of multiple-dose halofantrine in treatment of chloroquine-resistant falciparum malaria in children in Kenya. Lancet 1988;2:247-50.
27. Watkins WM, Winstanley PA, Mberu EK, et al. Halofantrine pharmacokinetics in Kenyan children with non-severe malaria. Br J Clin Pharmacol 1995;39:283-7.
28. Mbori-Ngacha DA, Onyango FE, Chunge C, et al. Efficacy of halofantrine in the treatment of uncomplicated falciparum malaria. East Afr Med J 1995;72:796-9.
29. Anabwani GM, Esamai FO, Menya DA A randomized controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine and fansidar in the treatment of uncomplicated malaria in children. East Afr Med J 1996;73: 155-8.
30. Falade CO, Salako LA, Sowunmi A, et al. Comparative efficacy of halofantrine, chloroquine and sulfadoxine-pyrimethamine for treatment of acute uncomplicated falciparum malaria in Nigerian children. Trans R Soc Trop Med Hyg 1997;91:58-62.
31. Nosten F, ter Kuile FO, Luxemburger C, et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet 1993; 341:1054-6.
32. Monlun E, le Metayer P, Szwandt S, et al. Cardiac implications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg 1995;89:430-3.
33. World Health Organization. Advances in malaria chemotherapy. WHO Tech Rep Ser 1973;529:30-2.
34. Smith PG, Morrow RH, eds. Methods for field trials of interventions against tropical diseases. Oxford, UK: Oxford University Press, 1991;283.